Hengrui Pharma(SH:600276) Mei Ri Jing Ji Xin Wen·2025-09-05 08:04Group 1 - Domestic pharmaceutical companies are experiencing a boost in market confidence as the value reassessment of Chinese innovative drug projects has begun in overseas transactions [1] - Heng Rui Medicine announced an exclusive licensing agreement with Braveheart Bio for an upfront payment of $65 million, with potential milestone payments reaching up to $1.013 billion related to clinical development and sales, along with corresponding sales royalties [1] - As of the end of August, the number of license-out transactions for domestic innovative drugs reached 83, a year-on-year increase of 57%, with a total disclosed amount of $84.531 billion, reflecting a year-on-year growth of 185% [1] Group 2 - The World Conference on Lung Cancer (WCLC) will take place from September 6 to 9 in Barcelona, Spain, where several leading innovative drug companies will unveil significant new products, providing more development opportunities and market attention for innovative drug enterprises [1] - The European Society for Medical Oncology (ESMO), one of the top three global oncology conferences, will be held in mid-October in Berlin, focusing on cutting-edge advancements in oncology, treatment strategies, and new drug development, with many Chinese pharmaceutical companies participating [2]